SGO Presents Its Awards for Best Gyn Oncology Papers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

CHICAGO--The Society of Gynecologic Oncologists (SGO) and the Gynecologic Cancer Foundation (GCF) presented awards in four categories at the SGO's 27th annual meeting in New Orleans. The awards are funded by the GCF and were chosen from the more than 115 abstracts presented at the meeting.

CHICAGO--The Society of Gynecologic Oncologists (SGO) and theGynecologic Cancer Foundation (GCF) presented awards in four categoriesat the SGO's 27th annual meeting in New Orleans. The awards arefunded by the GCF and were chosen from the more than 115 abstractspresented at the meeting.

The Best Science Award went to Pui Chun Cheng, MD, of the Universityof Southern California, for "Evidence that a locus whichescapes X inactivation on chromosome XQ controls early ovariantumorigenesis."

The President's Award for best all-around presentation went toThomas Wright, MD, of Columbia University Department of Pathologyfor "Correlation between HPV type and clonal status of cervicalintraepithelial lesions (SIL)."

The voting for best poster resulted in a tie, with awards goingto Zhiqiang Zou, MD, of the NCI, for "HPV-16 E7 cannot transformembryonic mouse fibroblasts lacking the insulin-like growth factor-1receptor gene," and to Richard R. Barakat, MD, of MemorialSloan-Kettering Cancer Center, for "The effect of adjuvanttamoxifen on the endometrium in women with breast cancer: An interimanalysis of a prospective study."

The Fellow's Award for outstanding paper by a resident or fellowwent to Jeffrey Skilling, MD, of the University of Iowa, for "Anabundance of p53 null mutations in ovarian cancer."

Recent Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.